Literature DB >> 25724490

Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.

Clothilde Roche1, Marie Besnier1, Roméo Cassel2, Najah Harouki1, David Coquerel1, Dominique Guerrot3, Lionel Nicol1, Emmanuelle Loizon2, Isabelle Remy-Jouet1, Christophe Morisseau4, Paul Mulder1, Antoine Ouvrard-Pascaud1, Anne-Marie Madec2, Vincent Richard5, Jeremy Bellien6.   

Abstract

This study addressed the hypothesis that inhibiting the soluble epoxide hydrolase (sEH)-mediated degradation of epoxy-fatty acids, notably epoxyeicosatrienoic acids, has an additional impact against cardiovascular damage in insulin resistance, beyond its previously demonstrated beneficial effect on glucose homeostasis. The cardiovascular and metabolic effects of the sEH inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB; 10 mg/l in drinking water) were compared with those of the sulfonylurea glibenclamide (80 mg/l), both administered for 8 wk in FVB mice subjected to a high-fat diet (HFD; 60% fat) for 16 wk. Mice on control chow diet (10% fat) and nontreated HFD mice served as controls. Glibenclamide and t-AUCB similarly prevented the increased fasting glycemia in HFD mice, but only t-AUCB improved glucose tolerance and decreased gluconeogenesis, without modifying weight gain. Moreover, t-AUCB reduced adipose tissue inflammation, plasma free fatty acids, and LDL cholesterol and prevented hepatic steatosis. Furthermore, only the sEH inhibitor improved endothelium-dependent relaxations to acetylcholine, assessed by myography in isolated coronary arteries. This improvement was related to a restoration of epoxyeicosatrienoic acid and nitric oxide pathways, as shown by the increased inhibitory effects of the nitric oxide synthase and cytochrome P-450 epoxygenase inhibitors l-NA and MSPPOH on these relaxations. Moreover, t-AUCB decreased cardiac hypertrophy, fibrosis, and inflammation and improved diastolic function, as demonstrated by the increased E/A ratio (echocardiography) and decreased slope of the end-diastolic pressure-volume relation (invasive hemodynamics). These results demonstrate that sEH inhibition improves coronary endothelial function and prevents cardiac remodeling and diastolic dysfunction in obese insulin-resistant mice.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  cardiac function; endothelium; insulin resistance; soluble epoxide hydrolase

Mesh:

Substances:

Year:  2015        PMID: 25724490      PMCID: PMC4551118          DOI: 10.1152/ajpheart.00465.2014

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  26 in total

1.  Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance.

Authors:  Ayala Luria; Ahmed Bettaieb; Yannan Xi; Guang-Jong Shieh; Hsin-Chen Liu; Hiromi Inoue; Hsing-Ju Tsai; John D Imig; Fawaz G Haj; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-12       Impact factor: 11.205

Review 2.  Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.

Authors:  Nikhil Tandon; Mohammed K Ali; K M Venkat Narayan
Journal:  Am J Cardiovasc Drugs       Date:  2012-02-01       Impact factor: 3.571

3.  Epoxyeicosatrienoic acid-induced relaxation is impaired in insulin resistance.

Authors:  A W Miller; C Dimitropoulou; G Han; R E White; D W Busija; G O Carrier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-10       Impact factor: 4.733

4.  Evidence of increased systemic glucose production and gluconeogenesis in an early stage of NIDDM.

Authors:  G Perriello; S Pampanelli; P Del Sindaco; C Lalli; M Ciofetta; E Volpi; F Santeusanio; P Brunetti; G B Bolli
Journal:  Diabetes       Date:  1997-06       Impact factor: 9.461

5.  Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure.

Authors:  Sébastien Banquet; Elodie Gomez; Lionel Nicol; Florence Edwards-Lévy; Jean-Paul Henry; Renhai Cao; Damien Schapman; Brigitte Dautreaux; Francoise Lallemand; Fabrice Bauer; Yihai Cao; Christian Thuillez; Paul Mulder; Vincent Richard; Ebba Brakenhielm
Journal:  Circulation       Date:  2011-08-08       Impact factor: 29.690

6.  Inhibition of soluble epoxide hydrolase reduces food intake and increases metabolic rate in obese mice.

Authors:  J M do Carmo; A A da Silva; J Morgan; Y-X Jim Wang; S Munusamy; J E Hall
Journal:  Nutr Metab Cardiovasc Dis       Date:  2010-12-28       Impact factor: 4.222

7.  Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure.

Authors:  Nassiba Merabet; Jeremy Bellien; Etienne Glevarec; Lionel Nicol; Daniele Lucas; Isabelle Remy-Jouet; Frederic Bounoure; Yvonne Dreano; Didier Wecker; Christian Thuillez; Paul Mulder
Journal:  J Mol Cell Cardiol       Date:  2011-12-06       Impact factor: 5.000

8.  Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension.

Authors:  Jeremy Bellien; Michele Iacob; Isabelle Remy-Jouet; Daniele Lucas; Christelle Monteil; Laurence Gutierrez; Cathy Vendeville; Yvonne Dreano; Alain Mercier; Christian Thuillez; Robinson Joannides
Journal:  Circulation       Date:  2012-03-13       Impact factor: 29.690

9.  Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats.

Authors:  Xueying Zhao; Aparajita Dey; Olga P Romanko; David W Stepp; Mong-Heng Wang; Yiqing Zhou; Liming Jin; Jennifer S Pollock; R Clinton Webb; John D Imig
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-09-02       Impact factor: 3.619

10.  Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice.

Authors:  Yan Liu; Huaixin Dang; Dan Li; Wei Pang; Bruce D Hammock; Yi Zhu
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

View more
  23 in total

1.  Computer-Aided Selective Optimization of Side Activities of Talinolol.

Authors:  Kerstin Hiesinger; Jan S Kramer; Janosch Achenbach; Daniel Moser; Julia Weber; Sandra K Wittmann; Christophe Morisseau; Carlo Angioni; Gerd Geisslinger; Astrid S Kahnt; Astrid Kaiser; Anna Proschak; Dieter Steinhilber; Denys Pogoryelov; Karen Wagner; Bruce D Hammock; Ewgenij Proschak
Journal:  ACS Med Chem Lett       Date:  2019-05-29       Impact factor: 4.345

2.  Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.

Authors:  John D Imig; Wojciech K Jankiewicz; Abdul H Khan
Journal:  Hypertension       Date:  2020-06-01       Impact factor: 10.190

Review 3.  Metabolic/inflammatory/vascular comorbidity in psychiatric disorders; soluble epoxide hydrolase (sEH) as a possible new target.

Authors:  W Swardfager; M Hennebelle; D Yu; B D Hammock; A J Levitt; K Hashimoto; A Y Taha
Journal:  Neurosci Biobehav Rev       Date:  2018-02-02       Impact factor: 8.989

Review 4.  Soluble epoxide hydrolase as a therapeutic target for obesity-induced disorders: roles of gut barrier function involved.

Authors:  Jianan Zhang; Maolin Tu; Zhenhua Liu; Guodong Zhang
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2020-09-19       Impact factor: 4.006

5.  Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice.

Authors:  Clothilde Roche; Dominique Guerrot; Najah Harouki; Thomas Duflot; Marie Besnier; Isabelle Rémy-Jouet; Sylvanie Renet; Anaïs Dumesnil; Annie Lejeune; Christophe Morisseau; Vincent Richard; Jeremy Bellien
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-05-27       Impact factor: 3.072

6.  Impact of the acute local inhibition of soluble epoxide hydrolase on diabetic skin microcirculatory dysfunction.

Authors:  Yann Savina; Thomas Duflot; Frederic Bounoure; Sylvain Kotzki; Pierre-Alain Thiebaut; Pierre-Alex Serreau; Mohamed Skiba; Jean-Michel Picquenot; Marie Cornic; Christophe Morisseau; Bruce Hammock; Laurent Imbert; Jean-Luc Cracowski; Vincent Richard; Matthieu Roustit; Jeremy Bellien
Journal:  Diab Vasc Dis Res       Date:  2019-07-03       Impact factor: 3.291

7.  Ephx2-gene deletion affects acetylcholine-induced relaxation in angiotensin-II infused mice: role of nitric oxide and CYP-epoxygenases.

Authors:  Ahmad Hanif; Matthew L Edin; Darryl C Zeldin; Mohammed A Nayeem
Journal:  Mol Cell Biochem       Date:  2019-12-04       Impact factor: 3.396

Review 8.  Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics.

Authors:  John D Imig
Journal:  Pharmacol Ther       Date:  2018-06-30       Impact factor: 12.310

9.  Lipidomic profiling reveals soluble epoxide hydrolase as a therapeutic target of obesity-induced colonic inflammation.

Authors:  Weicang Wang; Jun Yang; Jianan Zhang; Yuxin Wang; Sung Hee Hwang; Weipeng Qi; Debin Wan; Daeyoung Kim; Jia Sun; Katherine Z Sanidad; Haixia Yang; Yeonhwa Park; Jun-Yan Liu; Xinfeng Zhao; Xiaohui Zheng; Zhenhua Liu; Bruce D Hammock; Guodong Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-01       Impact factor: 11.205

10.  Soluble epoxide hydrolase deficiency attenuates lipotoxic cardiomyopathy via upregulation of AMPK-mTORC mediated autophagy.

Authors:  Luyun Wang; Daqiang Zhao; Liangqiu Tang; Huihui Li; Zhaoyu Liu; Jingwei Gao; Matthew L Edin; Huanji Zhang; Kun Zhang; Jie Chen; Xinhong Zhu; Daowen Wang; Darryl C Zeldin; Bruce D Hammock; Jingfeng Wang; Hui Huang
Journal:  J Mol Cell Cardiol       Date:  2020-12-27       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.